secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036395
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024
--------------------------------------------------------------------------------

- Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.
- Cash $111.5M at year-end 2023; expected to fund operations into 2H 2025.
- CAB-CTLA-4 (BA3071) cleared DLT at 700 mg; Phase 2 monotherapy data due 2Q 2024.
- CAB-ROR2-ADC (BA3021) Phase 2 melanoma/SCCHN fully enrolled; data readouts in May.
- CAB-AXL-ADC (BA3011) UPS registration trial enrollment ~20 patients due April; FDA meeting 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/0000950170-24-036395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/bcab-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer